Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Garmin Ltd. (GRMN) vs Revvity Inc (RVTY) Price & Performance

Garmin Ltd.Trade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Garmin Ltd. vs Revvity Inc — how do they compare? Garmin Ltd. trades at $307.81 (market cap $59.72B), while Revvity Inc trades at $114.87 (market cap $12.91B). The key difference: Garmin Ltd. is far larger — about 4.6× Revvity Inc's market cap, and Garmin Ltd. pays the higher dividend (1.36%). Which is the better fit depends on your goals.

GRMNRVTY
Market Cap
$59.72B$12.91B
Sector
TechnologyTechnology
52-Week High
$313.16$117.75
52-Week Low
$187.10$82.26
Enterprise Value
$57.23B$15.23B
Dividend Yield
1.36%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Garmin Ltd.

Garmin (GRMN) trades at $313.16, up 0.73% on the day and near its all-time high, with a bullish technical trend and strong support at $309. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.81 beating estimates of $2.30, and raised full-year guidance. Revenue growth accelerated to 11% in Q2 2026, driven by strong performance in the fitness segment, while net income margin improved to 24.47%.

The outlook remains positive given robust fundamentals and raised guidance, but risks include rich valuation multiples, potential growth deceleration, and insider selling. Analyst consensus is cautious with a hold-heavy rating, though the average price target of $318.67 suggests modest upside from current levels.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

About Garmin Ltd.

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Read more on GRMN

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY